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Background. Extensive immunopathology occurs in human immunodeficiency virus (HIV)/tuberculosis (TB) coinfection, but 
the underlying molecular mechanisms are not well-defined. Excessive matrix metalloproteinase (MMP) activity is emerging as a key 
process but has not been systematically studied in HIV-associated TB.
Methods. We performed a cross-sectional study of matrix turnover in HIV type 1 (HIV-1)–infected and –uninfected TB patients 
and controls, and a prospective cohort study of HIV-1–infected TB patients at risk of TB immune reconstitution inflammatory 
syndrome (TB-IRIS), in Cape Town, South Africa. Sputum and plasma MMP concentrations were quantified by Luminex, plasma 
procollagen III N-terminal propeptide (PIIINP) by enzyme-linked immunosorbent assay, and urinary lipoarabinomannan (LAM) 
by Alere Determine TB LAM assay. Peripheral blood mononuclear cells from healthy donors were cultured with Mycobacterium 
tuberculosis and extracellular matrix in a 3D model of TB granuloma formation.
Results. MMP activity differed between HIV-1–infected and –uninfected TB patients and corresponded with specific TB clin-
ical phenotypes. HIV-1–infected TB patients had reduced pulmonary MMP concentrations, associated with reduced cavitation, 
but increased plasma PIIINP, compared to HIV-1–uninfected TB patients. Elevated extrapulmonary extracellular matrix turnover 
was associated with TB-IRIS, both before and during TB-IRIS onset. The predominant collagenase was MMP-8, which was likely 
neutrophil derived and M. tuberculosis–antigen driven. Mycobacterium tuberculosis–induced matrix degradation was suppressed by 
the MMP inhibitor doxycycline in vitro.
Conclusions. MMP activity in TB differs by HIV-1 status and compartment, and releases matrix degradation products. Matrix 
turnover in HIV-1–infected patients is increased before and during TB-IRIS, informing novel diagnostic strategies. MMP inhibition 
is a potential host-directed therapy strategy for prevention and treatment of TB-IRIS.
Keywords. HIV-1; tuberculosis; immune reconstitution inflammatory syndrome; matrix metalloproteinase; procollagen III 
N-terminal propeptide. 
Tuberculosis (TB) and human immunodeficiency virus type 
1 (HIV-1) infection are global pandemics with complex inter-
play. HIV-1 increases the risk of TB, while TB accelerates HIV-1 
progression and is the commonest cause of HIV-related death [1]. 
Initiation of antiretroviral therapy (ART) reduces mortality, but is 
frequently complicated by development of tuberculosis immune 
reconstitution inflammatory syndrome (TB-IRIS) [2]. TB-IRIS is 
characterized by an acute inflammatory response to Mycobacterium 
tuberculosis (Mtb) presenting either in an uncharacteristically exag-
gerated form (unmasking IRIS), or as deterioration in a patient 
already receiving TB treatment (paradoxical IRIS) [3].
In immunocompetent adults, Mtb typically causes apical 
pulmonary disease with cavitation, which drives transmis-
sion and spread [4]. Conversely, in advanced HIV-1 infec-
tion, disseminated disease is more common and pulmonary 
cavitation less frequent [1, 5]. In paradoxical TB-IRIS, focal 
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inflammatory pathology primarily affects the lung and lymph 
nodes, causing tissue damage [6]. Although specific features 
have been described, such as hypercytokinemia and inflam-
masome activation, the final effectors of this immunopa-
thology are poorly defined [2, 6–9]. In HIV-uninfected TB 
patients, pulmonary immunopathology is driven by matrix 
metalloproteinases (MMPs), in particular the collagenase 
MMP-1, releasing matrix degradation products [10, 11]. 
Pulmonary MMPs are suppressed in advanced HIV-1 infec-
tion, providing a mechanism for reduced lung cavitation [12].
In this study, we systematically explored MMP activity and 
immunopathology in HIV-1–associated TB. We hypothesized 
that HIV-1–associated TB would be characterized by reduced 
MMP activity at TB diagnosis compared to HIV-uninfected 
TB, but that increased MMP activity would associate with 
inflammatory pathology during TB-IRIS. Our insights inform 
novel approaches to risk stratify and diagnose TB-IRIS, and 
also host-directed interventions to prevent pathology.
MATERIALS AND METHODS
Full methods are provided in the Supplementary Data. The 
study was approved by the University of Cape Town Human 
Research Ethics Committee (REF 516/2011). Cross-sectional 
study participants were healthy volunteers, patients with 
symptoms requiring assessment, or patients recently diag-
nosed with TB (Supplementary Table 1). Longitudinal study 
participants were ART-naive HIV-1–infected patients with 
a CD4 count <200 cells/µL and recently diagnosed TB. 
Longitudinal study visits occurred at TB diagnosis (TB0), 
ART initiation (ARV0), and 2 (ARV2) and 4 (ARV4) weeks 
of ART. Induced sputum and venous blood were collected. 
TB-IRIS diagnosis was assigned retrospectively on case 
review, using International Network for the Study of HIV-
associated IRIS (INSHI) criteria [3]. Chest radiographic 
inflammation (0–10) and sputum acid-fast bacilli (0–6) were 
scored as previously described [12].
Laboratory Analyses
Sputum and plasma samples were analyzed by Bio-Rad Bio-
Plex 200 using MMP beads (R&D Systems, Abingdon, United 
Kingdom). Procollagen III N-terminal propeptide (PIIINP) 
enzyme-linked immunosorbent assays (Cloud Clone Corp) 
and urine lipoarabinomannan (LAM) assays (Alere Determine 
TB LAM assay) were performed as per the manufacturers’ 
instructions.
PBMC Stimulation With H37Rv
Cryopreserved peripheral blood mononuclear cells (PBMCs) 
from a separate cohort of 22 TB-IRIS patients and 22 non-IRIS 
controls were stimulated with heat-killed H37Rv Mtb, as previ-
ously described [13]. Culture supernatants were harvested at 24 
hours and MMP-8 quantified by Luminex.
Extracellular Matrix 3D Modeling
Alginate microspheres incorporating healthy donor PBMCs and 
collagen were generated by bioelectrospray methodology using 
a Nisco encapsulator [14]. Stimulated cells were preinfected 
with ultraviolet-killed Mtb. DQ-labeled fluorescent gelatin or 
collagen (Invitrogen) was incorporated into the microspheres 
to quantitate matrix destruction [15]. Doxycycline (10 μg/mL 
or 20 μg/mL) was added to media after microsphere generation.
Statistical Analysis
Statistical analysis was performed using Prism 6 (GraphPad) 
and Stata version 14 software. Two-tailed Fisher exact or 
Mann-Whitney U test was performed for key comparisons. 
Correlations were assessed by Spearman rank-order correlation 
coefficients. Unadjusted and adjusted linear regression models 
were fitted to quantify effects and adjust for age, sex, and smok-
ing status. Repeated-measures 2-way analysis of variance with 
Tukey posttest comparison compared time-points and condi-
tions in the TB granuloma model.
RESULTS
Cross-sectional Study Participants
In the cross-sectional study, 227 participants were enrolled. Of 
these, 17 were excluded (unable to obtain samples, n = 8; diagnos-
tic uncertainty, n = 9), leaving 210 for analysis (Supplementary 
Figure  1). Participant demographic and clinical characteris-
tics are described in (Table 1). HIV-infected TB patients had a 
median CD4 count of 172 (interquartile range [IQR], 91–351) 
cells/µL. Age, sex, and body mass index (BMI) were similar in 
TB (HIV uninfected [HIV−]) and TB (HIV infected [HIV+]). 
However, smoking was more prevalent in TB (HIV−). TB (HIV−) 
and TB (HIV+) were associated with diverse pulmonary pathol-
ogies on chest radiograph. Frequency of cavities and median 
chest radiograph inflammation score were both reduced in TB 
(HIV+) compared with TB (HIV−). CD4 count and the number 
of cavities positively correlated (r = 0.357, P = .016), suggesting 
that destructive pulmonary pathology is reduced in advanced 
TB (HIV+). Microbiological confirmation of TB was similar for 
TB (HIV−) and TB (HIV+) (Supplementary Table 2). However, 
sputum smear positivity was more common in TB (HIV−).
Pulmonary MMP Profile Differs Between TB (HIV−) and TB (HIV+)
In sputum, we found multiple MMPs to be elevated in TB 
patients compared to controls (Figure  1A–G). In TB (HIV−), 
median MMP-1 was increased 35-fold and 33-fold compared 
with HIV-1–uninfected respiratory symptomatics and healthy 
controls, respectively. However, in TB (HIV+), lower median spu-
tum MMP-1, -2, -3, and -9 concentrations were observed com-
pared with TB (HIV−) (Figure 1A–C and 1F). Unadjusted and 
adjusted linear regression modeling of the effect of HIV and TB 
infection on log-transformed sputum MMP concentrations pro-
vided further evidence of elevated sputum MMPs with TB, and 
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Table 1. Demographics and Clinical Characteristics of Cross-sectional Study Participants
HIV-Uninfected HIV-Infected P Value
Diagnostic Category Healthy Control
Respiratory 
Symptomatic TB Patient Healthy Control
Respiratory 
Symptomatic TB Patient
TB (HIV−) vs 
TB (HIV+)
Frequency, No. 61 24 39 16 17 53 NA
Median age, y (IQR) 28 (24–34) 29 (25–38) 37 (30–42) 33 (28–36) 33 (30–37) 32 (29–36) .063
Female 19 (31) 5 (21) 13 (33) 11 (69) 10 (59) 25 (47) .205
Smoking history, current or 
former
43 (70) 16 (67) 23 (59) 5 (31) 6 (35) 14 (26) .003
Symptoms and examination findings
 Productive cough 0 (0) 6 (25) 31 (79) 0 (0) 5 (30) 30 (57) .027
 Nonproductive cough 0 (0) 6 (25) 10 (26) 0 (0) 8 (47) 21 (40) .186
 Hemoptysis 0 (0) 0 (0) 6 (15) 0 (0) 0 (0) 8 (15) 1.000
 Night sweats 1 (2) 8 (33) 27 (69) 0 (0) 8 (47) 44 (83) .138
 Weight loss 6 (10) 5 (21) 20 (51) 3 (19) 4 (24) 30 (57) .675
Median symptom duration, 
d (IQR)
NA 14 (5–75) 28 (14–30) NA 30 (30–60) 30 (14–30) .800
Median BMI 22.9 (21.2–26.4) 21.9 (19.9–24.2) 21.6 (20.1–25.8) 26.9 (22.8–32.9) 27 (20.4–31.8) 22.9 (20.4–25.3) .493
Median temperature, °C 
(IQR)
36.1 (35.8–36.3) 35.9 (35.6–36.2) 36.2 (35.9–36.6) 36.1 (35.8–36.5) 35.9 (35.6–36.4) 36.6 (36.0–37.5) .054
Median heart rate, beats/ 
min (IQR)
72 (68–78) 70 (66–78) 80 (68–88) 74 (70–82) 70 (64–83) 84 (77–98) .009
Median systolic blood pres-
sure, mm Hg
120 (119–130) 130 (120–133) 120 (110–120) 120 (112–128) 120 (111–130) 117 (110–120) .617
Median diastolic blood 
pressure, mm Hg
80 (70–86) 80 (71–85) 80 (70–80) 80 (70–83) 80 (76–90) 75 (70–80) .589
Median respiratory rate, 
breaths/min (IQR)
16 (16–18) 18 (16–20) 20 (16–24) 18 (16–20) 17 (16–20) 23 (18–28) .074
Extrapulmonary TB features NA NA 8 (21) NA NA 26 (49) .008
Laboratory parameters
 Median hemoglobin 
concentration, g/dL 
(IQR)
14.3 (13.3–15.0) 14.3 (13.8–15.3) 12.7 (12.2–13.7) 12.6 (11.8–13.7) 13.2 (12.7–13.9) 10.7 (9.4–12.0) <.0001
 Median total white cell 
count, ×109/L (IQR)
6.06 (4.84–7.48) 5.81 (4.58–7.55) 7.45 (5.84–9.00) 4.95 (4.19–5.88) 5.24 (4.28–6.28) 5.48 (4.00–7.73) .002
 Median neutrophil count 
(IQR)
3.32 (2.39–4.53) 3.32 (2.21–4.88) 5.11 (3.4–6.71) 2.53 (1.9–3.59) 2.32 (1.9–3.45) 3.54 (2.33–5.34) .009
 Median neutrophil % (IQR) 55.2 (47.5–61.4) 55.5 (46.4–63.6) 65.8 (58.2–75.5) 51.8 (46.6–59.3) 51.4 (42.5–61.9) 68.9 (57.5–78.1) .910
 Median lymphocyte 
count (IQR)
1.99 (1.61–2.40) 1.8 (1.24–2.03) 1.57 (1.20–2.02) 1.53 (1.38–2.17) 1.81 (1.25–2.50) 1.08 (0.59–1.59) .003
 Median lymphocyte % 
(IQR)
32.7 (27.9–40.2) 32.6 (24.8–42.6) 21 (14.5–29.3) 32.3 (24.5–39.8) 34 (26.8–41.4) 20.8 (13.7–29.8) .809
 Median monocyte count 
(IQR)
0.35 (0.26–0.43) 0.36 (0.23–0.44) 0.55 (0.39–0.69) 0.37 (0.29–0.43) 0.27 (0.22–0.42) 0.34 (0.26–0.45) <.0001
 Median monocyte % 
(IQR)
5.2 (4.4–7.1) 5.6 (4.5–6.5) 6.6 (5.2–9.8) 6.9 (6.1–9.0) 5.9 (4.8–7.6) 6.8 (4.55–8.4) .150
 Median platelet count 
(IQR)
309 (247–355) 316 (262–380) 505 (355–579) 247 (182–327) 325 (263–377) 357 (249–464) .001
 Median C-reactive pro-
tein, mg/L (IQR)
1.3 (0.9–4.9) 3.3 (0.9–8.3) 46.9 (7.8–82.7) 1.4 (0.9–2.6) 2.7 (1.5–11.0) 57.1 (18.5–85.7) .304
 Median albumin concen-
tration, g/dL (IQR)
47 (44–49) 47 (44–50) 40 (37–43) 43 (42–46) 44 (42–46) 34 (30–38) <.0001
 Median CD4 count, 
cells/µL (IQR)
NA NA NA 309 (194–409) 373 (151–526) 172 (91–351) NA
 Median CD4 % (IQR) NA NA NA 15.8 (4.6–23.4) 18.5 (12.0–23.9) 12.7 (9.5–18.9) NA
Radiographic features
 Median chest radiograph 
inflammation score (IQR)
0 (0–0) 1 (0–2) 6 (4–8) 0 (0–0) 1 (0–1) 4 (3–8) .047
 Cavities present on chest 
radiograph
0 (0) 0 (0) 27 (69) 0 (0) 0 (0) 15 (28) <.001
 Miliary TB NA NA 1 (3) NA NA 8 (16) .071
 Chest radiograph not 
available
5 (8) 1 (4) 1 (3) 0 (0) 1 (2) 4 (7) .391
Data are presented as No. (%) unless otherwise indicated. P values are for Fisher exact or Mann-Whitney U test.
Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus; IQR, interquartile range; NA, not applicable; TB, tuberculosis.
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/65/1/121/3799983 by St G
eorge's U
niversity of London user on 05 February 2019
124 • CID 2017:65 (1 July) • Walker et al
reduced sputum MMPs in TB (HIV+) compared with TB (HIV−), 
after adjusting for age, sex, and smoking status (Supplementary 
Table 3). The greatest effect was for MMP-1 and MMP-3. We did 
not adjust for BMI as no association was observed with MMP 
concentrations. Sputum MMP concentrations by sex are reported 
in Supplementary Figure 2 and Supplementary Table 4.
103
104
105
106
107
108
Sp
ut
um
 M
M
P-
9 
(p
g/
m
l)
102
103
104
105
106
107
Sp
ut
um
 M
M
P-
8 
(p
g/
m
l)
BA
DC
FE
**** 
**** 
**** 
*
**
10-1
100
101
102
103
104
105
106 **
Sp
ut
um
 M
M
P-
1 
(p
g/
m
l)
101
102
103
104
105
S
pu
tu
m
 M
M
P
-2
 (
pg
/m
l)
****** *
HC
 (H
IV
– )
RS
 (H
IV
– ) 
TB
 (H
IV
– )
HC
 (H
IV
+ )
RS
 (H
IV
+ )
TB
 (H
IV
+ )
HC
 (H
IV
– )
RS
 (H
IV
– ) 
TB
 (H
IV
– )
HC
 (H
IV
+ )
RS
 (H
IV
+ )
TB
 (H
IV
+ )
HC
 (H
IV
– )
RS
 (H
IV
– ) 
TB
 (H
IV
– )
HC
 (H
IV
+ )
RS
 (H
IV
+ )
TB
 (H
IV
+ )
HC
 (H
IV
– )
RS
 (H
IV
– ) 
TB
 (H
IV
– )
HC
 (H
IV
+ )
RS
 (H
IV
+ )
TB
 (H
IV
+ )
HC
 (H
IV
– )
RS
 (H
IV
– ) 
TB
 (H
IV
– )
HC
 (H
IV
+ )
RS
 (H
IV
+ )
TB
 (H
IV
+ )
HC
 (H
IV
– )
RS
 (H
IV
– ) 
TB
 (H
IV
– )
HC
 (H
IV
+ )
RS
 (H
IV
+ )
TB
 (H
IV
+ )
HC
 (H
IV
– )
RS
 (H
IV
– ) 
TB
 (H
IV
– )
HC
 (H
IV
+ )
RS
 (H
IV
+ )
TB
 (H
IV
+ )
10-1
100
101
102
103
104
105
Sp
ut
um
 M
M
P-
1 
(p
g/
m
l)
10-1
100
101
102
103
104
105
Sp
ut
um
 M
M
P-
3 
(p
g/
m
l)
**** **** 
**** **** 
*
G
102
103
104
105
106
Sp
ut
um
 M
M
P-
7 
(p
g/
m
l)
H
100
101
102
103
104
105
Sp
ut
um
 M
M
P-
10
 (p
g/
m
l)
Bilateral          -                 +                 -                 +  
HIV Status      -                 -                 +                 +
**** 
***** 
Figure 1. Pulmonary matrix metalloproteinase (MMP) concentrations are increased in tuberculosis (TB) and differ by human immunodeficiency virus (HIV) serostatus. 
Pulmonary TB is associated with increased MMP-1, -2, -3, -7, -8, -9, and -10 concentrations in sputum in comparison to respiratory symptomatic (RS) and healthy controls (HC) 
(A–G). Comparison of TB (HIV−) with TB (HIV+) demonstrated lower median sputum MMP-1 (A), -2 (B), -3 (C), and -9 (F) concentrations in TB (HIV+). Median MMP-8 was also 
reduced in TB (HIV+) compared to TB (HIV−), although to a lesser extent (E). TB (HIV−) patients with bilateral radiographic abnormalities had elevated sputum MMP-1, compared 
with TB (HIV−) patients with unilateral abnormalities (H). However, in TB (HIV+), MMP-1 was similar in patients with bilateral and unilateral chest radiographic involvement 
(H). In A–G, boxes represent the first and third quartiles and horizontal bars within indicate median values; whiskers indicate minimum and maximum values. In (H), triangles 
represent TB (HIV−) and circles represent TB (HIV+). Horizontal bars between the datasets indicate Mann-Whitney U test comparisons; in A–G comparisons between TB (HIV−) 
and HC (HIV−), TB (HIV+) and HC (HIV+), and TB (HIV+) and TB (HIV−) are shown. *P < .05, **P < .01, ****P < .0001. 
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We related radiographic features with MMP concentrations. 
Sputum MMP-1 positively correlated with cavity frequency in 
TB (HIV−) and TB (HIV+) (r = 0.592 and r = 0.533, respectively, 
both P < .0001). In TB (HIV−), the chest radiograph inflamma-
tion score positively correlated with sputum MMP-1 and MMP-3 
(r = 0.452 and r = 0.453, both P = .011). However, in TB (HIV+), 
no such correlation was evident (Supplementary Table 5). In TB 
(HIV−) patients with bilateral chest radiograph lesions, median 
sputum MMP-1 was increased 85-fold compared to those with 
unilateral lesions. However, in TB (HIV+) patients with bilateral 
chest radiograph lesions, sputum MMP-1 was not increased 
compared to patients with unilateral lesions (Figure 1F).
In TB patients, sputum smear and culture positivity were 
associated with increased sputum MMP-1 and MMP-3, 
which were positively correlated with acid-fast bacilli score 
(Supplementary Figures 3 and 4). Together, these data support 
a role for sputum MMPs in pulmonary TB–driven matrix deg-
radation. However, divergent MMP upregulation occurs in TB 
(HIV−) and TB (HIV+), with reduced sputum MMP-1 in TB 
(HIV+) associated with lesser pulmonary matrix destruction.
Plasma PIIINP Is Elevated in TB and Further Increased in HIV-1–Associated 
TB
MMP activity releases matrix degradation products such as 
PIIINP from type III collagen. Analysis of plasma in a subgroup 
of 73 patients of mixed HIV serostatus in the cross-sectional 
study (39 TB, 34 control) showed that PIIINP concentrations 
were elevated in TB patients compared to control patients 
(Figure 2A). Median PIIINP values were 25 278 (IQR, 11 787–
45 071) pg/mL and 3888 (IQR, 1278–10 367) pg/mL, respec-
tively (P < .0001). When analyzed according to HIV status, both 
TB (HIV−) and TB (HIV+) patients had higher plasma PIIINP 
concentrations than corresponding controls. However, we unex-
pectedly found that plasma PIIINP was further elevated in TB 
(HIV+) compared to TB (HIV−) (Figure 2B), despite the reduced 
sputum MMP concentrations. To investigate further, we related 
plasma PIIINP to clinical features. Plasma PIIINP negatively 
correlated with peripheral blood CD4 count (r = −0.435, P = 
.006; Figure 2C) and hemoglobin concentration (r = −0.557, P < 
.0001), and positively correlated with HIV-1 viral load (r = 0.544, 
P = .002; Figure 2D). Plasma PIIINP was significantly elevated in 
TB patients with extrapulmonary TB compared to those without 
(Figure 2E). Taken together with the sputum MMP analysis, this 
suggested that elevated plasma PIIINP in TB (HIV+) was due to 
increased extrapulmonary MMP activity.
HIV Coinfection Does Not Suppress Systemic MMP Activity in TB
We therefore measured plasma MMP concentrations in the 
cross-sectional cohort (Figure  2F and 2G and Supplementary 
Figures 5 and 6). In TB (HIV−), MMP-1, MMP-7, and MMP-8 
were elevated compared with HIV-uninfected controls, while 
plasma MMP-3, -9, and -10 were similar and MMP-2 was 
reduced. In TB (HIV+), the collagenases MMP-1 and MMP-8 
were elevated in TB (HIV+) compared with HIV-infected con-
trols (Figure 2F and 2G) and, in contrast to the findings in spu-
tum, were not reduced compared to TB (HIV−).
Paradoxical TB-IRIS Is Associated With Systemic Inflammation at TB 
Diagnosis
In the longitudinal cohort, 57 ART-naive TB patients with 
advanced HIV-1 (CD4 count <200 cells/µL) were enrolled 
(Supplementary Figure 1). Paradoxical TB-IRIS was diagnosed in 
29 of 49 (59.2%) patients who completed follow-up. Of these, 25 
met the INSHI criteria for TB-IRIS and 4 were probable TB-IRIS. 
Twenty patients did not develop TB-IRIS and were designated 
non-IRIS controls. Two non-IRIS controls were excluded (1 
likely an elite controller having an undetectable HIV-1 viral load 
and therefore considered immunologically distinct, 1 developed 
hepatotoxicity on TB treatment delaying ART initiation), leaving 
47 (29 TB-IRIS, 18 non-IRIS) patients in the final analysis.
Demographic and clinical characteristics of longitudinal 
study participants are reported in Supplementary Table 6. The 
median time to TB-IRIS symptom onset was 6 (IQR, 3.5–9.5; 
range, 1–23) days after ART initiation and patients presented 
with symptoms at a median of 14 (IQR, 9–15; range, 4–29) 
days. Clinical features of TB-IRIS presentations are reported in 
Supplementary Table 7. Predominant symptoms and signs were 
constitutional (n = 29 [100%]) and pulmonary (n = 27 [93.1%]). 
Patients with TB-IRIS were unwell: hospital admission was 
required in 13 (45%) TB-IRIS patients during study follow-up, 
compared with only 1 (6%) non-IRIS control (P = .007).
Clinical signs that characterized TB-IRIS patients were ele-
vated heart rate (Figure  3A) and respiratory rate (Figure  3B) 
at TB diagnosis, as well as at TB-IRIS presentation, compared 
to non-IRIS controls. In both TB-IRIS and non-IRIS patients, 
CD4 count increased in the first 2 weeks of ART (Figure 3C), 
and HIV-1 viral load reduced (Figure  3D), although median 
HIV-1 viral load was higher in TB-IRIS patients than in 
non-IRIS patients at TB diagnosis and at ARV2. Markedly 
increased C-reactive protein occurred at TB-IRIS presentation 
(Figure 3E). Median lymphocyte counts were lower in TB-IRIS 
patients at all timepoints (Figure 3F), whereas neutrophil counts 
(Figure 3G) and monocyte counts (Figure 3H) were increased 
at ARV2. Therefore, TB-IRIS was frequent, associated with sig-
nificant morbidity and characterized by marked features of sys-
temic inflammation at TB diagnosis, which partially resolved 
with TB treatment but recurred at the time of TB-IRIS.
Immunopathology in Paradoxical TB-IRIS Is Associated With Increased 
MMP Activity
To investigate the mechanism of immunopathology in TB-IRIS, 
we measured sputum MMPs and plasma PIIINP longitudinally. 
We observed no consistent association of increased sputum 
MMPs with TB-IRIS diagnosis (Supplementary Figure  7 and 
Supplementary Tables 8 and 9). In contrast, plasma PIIINP was 
elevated in TB-IRIS compared to non-IRIS patients both at the 
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Figure 2. Tuberculosis (TB) increases systemic extracellular matrix turnover, which is further augmented by human immunodeficiency virus (HIV) coinfection. Plasma pro-
collagen III N-terminal propeptide (PIIINP) concentration was elevated in TB patients compared to respiratory symptomatic (RS) and healthy controls (HC) (A). TB (HIV+) and TB 
(HIV−) patients had higher plasma PIIINP concentrations than corresponding controls (B). In contrast to sputum matrix metalloproteinases (MMPs), plasma PIIINP was further 
elevated in TB (HIV+) compared with TB (HIV−). In HIV+ patients, plasma PIIINP concentration and peripheral blood CD4 cell count negatively correlated (C), whereas HIV-1 viral 
load positively correlated with PIIINP concentration (D). Plasma PIIINP was elevated in patients with extrapulmonary TB (EPTB) compared to those without EPTB (E). Plasma 
MMP-1 (F) and plasma MMP-8 (G) were elevated in TB (HIV−) and TB (HIV+) compared to respective RS and HC, and did not differ by HIV serostatus in TB patients. Boxes rep-
resent the first and third quartiles and horizontal bars within indicate median values; whiskers indicate minimum and maximum values. Horizontal bars between the datasets 
indicate Mann-Whitney U test comparisons. *P < .05, **P < .01, ***P < .001, ****P < .0001. Correlations were performed using Spearman rank-order correlation coefficient.
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Figure 3. Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) is characterized by systemic inflammation at TB diagnosis and during TB-IRIS. 
We studied 47 antiretroviral therapy (ART)–naive TB patients with advanced human immunodeficiency virus (HIV; CD4 count <200 cells/µL) at enrollment, who underwent 
clinical observation at TB diagnosis (TB0) and biweekly for the first 4 weeks of ART (ARV0, ARV2, ARV4). TB-IRIS patients were characterized by elevated heart rate (A) and 
elevated respiratory rate (B), compared to non-IRIS controls. CD4 count increased in both TB-IRIS patients and non-IRIS controls following ART initiation (C) and concurrently 
HIV-1 viral load reduced (D), although median HIV-1 viral load was higher in TB-IRIS patients than in non-IRIS patients at TB diagnosis and at ARV2. Elevated C-reactive 
protein was a feature of TB-IRIS onset (E). Median lymphocyte counts were lower in TB-IRIS patients at all timepoints (F), whereas neutrophil counts (G) and monocyte counts 
(H) were increased at ARV2 and to a lesser extent at ARV4. In A, B, F, G, and H, boxes represent the first and third quartiles, horizontal bars within the median values, and 
whiskers the minimum and maximum values. In C and D, data are median values (TB-IRIS, filled circles; non-IRIS, open squares) linked by horizontal lines, and interquartile 
ranges are shown by vertical bars. In E, individual data points are shown, including results for unscheduled visits (ARV1, 3, 5, and 6 representing visits at 1, 3, 5 and 6 weeks 
of ART, respectively), and horizontal lines represent the median. In all panels, asterisks indicate Mann-Whitney U test comparisons; summary P values: *<.05 and **<.01.
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time of TB diagnosis, and during TB-IRIS (ARV2 and ARV4), 
but not at ART initiation (Figure 4A). At TB0, patients who later 
developed TB-IRIS had a median plasma PIIINP more than dou-
ble that in non-IRIS controls: 43 600 (IQR, 30 021–63 913) pg/mL 
vs 21 651 (IQR, 17 757–33 196) pg/mL, respectively (P = .036).
To investigate the hypothesis that the elevated PIIINP resulted 
from systemic MMP activity in TB-IRIS, we examined plasma 
MMP concentrations. Plasma MMP-1, -3, and -8 were ele-
vated in TB-IRIS compared to non-IRIS patients (Figure 4B–D 
and Supplementary Tables 8 and 10). MMP-8 (neutrophil 
collagenase) was the most significantly increased, in a similar 
pattern to PIIINP, suggesting that systemic collagenase activ-
ity caused matrix degradation and PIIINP production during 
TB-IRIS. Supporting this, MMP-8 correlated with plasma PIIINP 
concentration (r = 0.435, P < .0001) (Figure 4E). As neutrophils 
may be a source of MMP-8 and neutrophil counts were elevated 
in TB-IRIS patients, we assessed the correlation between plasma 
MMP-8 and neutrophil count and percentage. MMP-8 concen-
tration positively correlated with neutrophil count (r = 0.617, 
P < .0001; Figure 4F) and percentage (r = 0.664, P < .0001).
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Figure 4. Immunopathology in paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) is associated with increased matrix metalloproteinase 
(MMP) activity. Plasma procollagen III N-terminal propeptide (PIIINP) was elevated in TB-IRIS patients compared to non-IRIS control patients at the time of TB diagnosis and 
also at IRIS onset (A). Plasma MMPs were elevated in TB-IRIS compared to non-IRIS controls, including MMP-1 (B), MMP-3 (C), and, most consistently, MMP-8 (D). Plasma 
MMP-8 positively correlated with plasma PIIINP (E) and also with neutrophil count (F). In A–D, boxes represent the first and third quartiles; horizontal bars within median 
values and whiskers minimum and maximum values. Comparisons are by Mann-Whitney U test. *P < .05, **P < .01, ***P < .001. In E and F, individual data points are plotted 
by filled circles. Spearman rank-order correlation coefficient r and P values are reported for correlations.
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Mtb Antigen Is Associated With Elevated MMP Concentrations in TB-IRIS
We further hypothesized that increased MMP activity in 
TB-IRIS patients was secondary to increased mycobacterial 
antigen load. The frequency of sputum smear positivity, culture 
positivity, smear score, and time to culture positivity was similar 
between TB-IRIS and non-IRIS patients. However, these indi-
ces represent Mtb antigen in the pulmonary compartment. We 
therefore measured urinary LAM, indicative of disseminated 
TB, in patients for whom a urine sample was available. In an 
adjusted regression analysis, IRIS was associated with increased 
odds of a positive urine LAM finding (odds ratio, 10.9 [95% 
confidence interval, 1.02–115.88], P  =  .048; Supplementary 
Table 11). In an analysis of TB-IRIS patients only, those LAM 
positive had higher plasma MMP-3, MMP-7, and MMP-8 than 
TB-IRIS patients who were LAM negative (Figure 5A).
We next examined the effect of antigen stimulation on MMP 
activity in TB-IRIS patients. We studied MMP-8 concentrations 
in PBMC culture supernatants from a previously published 
cohort of TB-IRIS and non-IRIS controls sampled at the time of 
TB-IRIS onset [13]. In TB-IRIS patients, MMP-8 secretion was 
increased following stimulation with heat-killed H37Rv Mtb 
compared to non-IRIS controls (Figure 5B).
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Figure 5. Elevated matrix metalloproteinases (MMPs) associate with increased tuberculosis (TB) antigen load, and Mycobacterium tuberculosis (Mtb)–driven MMP activity 
is inhibited by doxycycline (Doxy/Dox). Tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) patients with positive urinary lipoarabinomannan (LAM) had 
increased plasma MMP-3, MMP-7, and MMP-8 compared with TB-IRIS patients who were LAM negative (A). Plasma MMP-3 was higher at TB diagnosis (TB0) but not at 2 
weeks of antiretroviral therapy (ARV2), whereas MMP-7 and MMP-8 were most significantly increased at ARV2. MMP-8 concentrations were measured in culture superna-
tants of peripheral blood mononuclear cells (PBMCs) stimulated with heat-killed H37Rv Mtb in a cohort of 22 TB-IRIS patients and 22 non-IRIS controls (B). After stimulation, 
MMP-8 secretion was greater from TB-IRIS PBMCs than non-IRIS controls. In a 3D cell culture model of TB, microspheres were impregnated with ultraviolet-killed Mtb-
stimulated PBMCs and either DQ-gelatin or DQ-collagen (DQC), which increase in fluorescence when cleaved. Mtb stimulation increased total gelatin degradation within 
microspheres compared to control PBMCs (C). Addition of doxycycline to the surrounding cell culture media inhibited extracellular matrix breakdown (D). Similarly, doxycycline 
suppressed Mtb-driven collagen degradation in a dose-dependent manner (E). In A and B, horizontal lines indicate medians, and comparisons between groups are by Mann-
Whitney U test analysis; in C–E, means and standard error of the mean are shown and analyses are by 2-way repeated measures analysis of variance, with Tukey posttest 
comparison. Comparisons shown are for gelatin + PBMC + Mtb compared to gelatin + PBMC (C) and doxycycline 20 μg/mL compared to Mtb alone. Summary P values: *<.05, 
**<.01, ****<.0001.
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Doxycycline Suppresses Mtb-Driven Matrix Degradation
Doxycycline is a licensed MMP inhibitor and reduces colla-
genase activity. We studied the inhibitory effect of doxycycline in 
a 3D cell culture model of TB that recapitulates key components 
of human granuloma formation using a functional readout of 
matrix destruction [15]. Stimulation of PBMCs with ultravio-
let-killed Mtb increased degradation of gelatin within micro-
spheres over time compared to uninfected cells (Figure  5C). 
Doxycycline in cell culture media around microspheres inhib-
ited this breakdown (Figure  5D). Similarly, doxycycline sup-
pressed Mtb-driven collagen degradation in a dose-dependent 
manner (Figure 5E).
DISCUSSION
Despite some advances, treatment of TB remains a great 
challenge, due to lengthy regimens, poor side-effect profiles, 
drug interactions, and drug resistance [16]. These problems 
are further compounded by HIV-1 coinfection [17]. Host-
directed therapies have been proposed as a novel strategy to 
improve treatment outcome, but their development requires 
greater understanding of pathological and protective immune 
responses [16, 18]. In this study, we identified key differences 
between MMPs that cause immunopathology in TB dependent 
on HIV-1 status and characterized MMPs in TB-IRIS. In HIV-
uninfected TB patients, MMP activity was prominent in the 
pulmonary compartment and MMP-1 was dominant, whereas 
in HIV-1–infected patients, higher plasma PIIINP may repre-
sent MMP-driven tissue destruction at extrapulmonary sites, 
with MMP-8 as the principal protease. We identified PIIINP as 
a pathological marker of excessive MMP activity at TB diagno-
sis and during TB-IRIS, with potential to risk stratify individ-
uals prior to ART and also to diagnose TB-IRIS. In addition, 
the MMP inhibitor doxycycline has potential as a host-directed 
therapy to prevent TB-IRIS.
Our findings of increased sputum MMPs in TB, and reduced 
sputum MMPs in HIV-1-associated TB, concur with findings in 
previous smaller studies [10, 12]. We previously reported that 
multiple MMP genes were upregulated in TB-IRIS PBMCs res-
timulated with heat-killed H37Rv Mtb [13]. MMP-8 was not 
among the upregulated genes. However, while most MMPs are 
regulated at the transcriptional level, MMP-8 is predominantly 
presynthesized in neutrophils and therefore may not be identi-
fied by gene expression analysis. We have previously reported 
compartmentalized inflammatory responses in HIV-infected 
patients with tuberculous meningitis (TBM), in cerebrospinal 
fluid (CSF) and plasma, with elevated CSF MMP-1, -7, and -10 in 
TBM-IRIS compared with non-IRIS controls, although MMP-8 
was not studied [19]. Ravimohan et al found that an increase in 
plasma MMP-8 at week 4 of ART relative to baseline pre-ART 
levels was associated with increased TB-IRIS risk and abnor-
mal pulmonary function tests after TB treatment completion, 
consistent with our finding that MMP-8 is a key collagenase in 
TB-IRIS [20]. In addition, we have previously demonstrated that 
neutrophils were an important source of MMP-8 in TB and that 
neutrophilia was associated with poor outcomes [21, 22].
Dysregulated innate immune responses have been implicated 
in TB-IRIS pathophysiology [6, 7, 9, 23]. Elevated innate proin-
flammatory cytokines, monocyte activation, cytotoxicity, and 
inflammasome activation have been associated with TB-IRIS, 
implying global activation of the innate immune response [6, 
8, 9, 24, 25], but these studies do not identify the ultimate effec-
tors of tissue destruction. An association between TB-IRIS and 
mycobacterial antigen load has been demonstrated [9, 26]. 
Our results suggest that either Mtb antigen leads to increased 
MMP activity or that increased MMP activity in patients 
who develop TB-IRIS causes increased extracellular matrix 
destruction, thereby increasing detection of urinary antigen. In 
HIV-1–infected TB patients on ART, elevated hyaluronic acid, a 
glycosaminoglycan component of the extracellular matrix, was 
associated with poor outcomes including death [25]. Therefore, 
matrix degradation products may have a prognostic role in 
HIV-1–associated TB and indicate high TB-IRIS risk.
Currently, the only established immunomodulatory strategy 
for TB or TB-IRIS is corticosteroid therapy, used adjunctively in 
central nervous system and pericardial TB, and in treatment of 
paradoxical TB-IRIS [27]. Corticosteroids suppress Mtb-driven 
MMPs and this may contribute to their beneficial effects [28–
30]. Our 3D model of TB granuloma formation demonstrates 
the potential of doxycycline to inhibit Mtb-driven matrix deg-
radation. Extracellular matrix integrity favors host cell survival 
in Mtb infection, and therefore matrix-protective strategies may 
improve outcome in TB without exacerbating HIV-1–related 
immune compromise [31]. Doxycycline, a licensed MMP inhibi-
tor, is cheap, safe, and widely available and could be studied as an 
immunomodulatory adjuvant in TB treatment, with the added 
benefit of bacteriostatic antimycobacterial activity [12, 32].
We report a large study investigating mechanisms of immuno-
pathology in TB. However, as an observational study, we cannot 
attribute causality, nor exclude the possibility that unmeasured 
confounding factors contributed to measured associations. We 
adjusted for sex and smoking status, factors that have been asso-
ciated with divergent MMP responses, but cannot exclude alter-
native confounders [33, 34]. The incidence of TB-IRIS (59%) was 
high, causing significant morbidity. Sputum samples were not 
available from some severely unwell TB-IRIS patients who were 
unable to expectorate, which may have resulted in an underesti-
mation of effect in the longitudinal sputum analysis.
In summary, our work supports a central role for MMPs in 
causing tissue damage in TB and TB-IRIS, generating matrix 
degradation products. Differential MMP expression and com-
partmentalization occurs in HIV-1–infected patients. Systemic 
MMP-8 is the dominant protease in TB-IRIS, in contrast to 
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pulmonary-localized MMP-1 in HIV-uninfected TB patients. 
Matrix degradation products are promising biomarkers of 
TB-IRIS risk prior to and during clinical onset. Doxycycline, 
an MMP inhibitor, may prevent immunopathology in TB-IRIS.
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